Drug Trial Radar · NCT07489131
Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants With Diabetic Macular Edema
Last checked: Nov 19, 2026Latest source record: Apr 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
256
Planned (sponsor's estimate)
Start
Apr 22, 2026
Primary completion
Jul 2027
Study completion Jan 2028
Sponsor
- Lead sponsor
- Alvotech Swiss AGIndustry
- Sponsor type
- Industry
- First posted
- Mar 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Randomized, Double-masked, Parallel-group, Multicenter Clinical Study to Evaluate the Efficacy and Safety of AVT29 Compared with Eylea HD in Participants with Diabetic Macular Edema.
Conditions
- Diabetic Macular Edema
Interventions
AVT29 (proposed aflibercept HD biosimilar)Drug
Patients will receive IVT injections of AVT29
Eylea HD (aflibercept HD)Drug
Patients will receive IVT injections of Eylea HD
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline to Week 8 in BCVA as measured by ETDRS letter scoreTime frame: week 8
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Site 3004
Budapest, Hungary · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.